LPL Financial LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

LPL Financial LLC raised its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 12.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,154 shares of the company’s stock after buying an additional 6,310 shares during the quarter. LPL Financial LLC owned about 0.15% of Entrada Therapeutics worth $954,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in TRDA. KLP Kapitalforvaltning AS purchased a new position in shares of Entrada Therapeutics during the fourth quarter worth about $36,000. AlphaQuest LLC purchased a new position in Entrada Therapeutics in the 4th quarter worth approximately $70,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Entrada Therapeutics in the 4th quarter worth $137,000. SG Americas Securities LLC raised its position in shares of Entrada Therapeutics by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock valued at $243,000 after buying an additional 4,291 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Entrada Therapeutics by 34.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after buying an additional 3,644 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Price Performance

Shares of NASDAQ TRDA opened at $8.13 on Monday. The stock has a market capitalization of $305.65 million, a P/E ratio of 5.11 and a beta of 0.04. Entrada Therapeutics, Inc. has a one year low of $7.10 and a one year high of $21.79. The firm’s 50 day simple moving average is $10.30 and its two-hundred day simple moving average is $14.58.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.66) by $0.69. The company had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. As a group, equities analysts expect that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Monday, March 31st.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.